Student Opinion: Stem Cell Treatment Advances Towards A Brighter Future – The Peoples Vanguard of Davis

Cornea grafts can help to restore vision. Scientists in Japan are planning to graft tissue grown from stem cells. Credit: Burger/Phanie/Science Photo Library

By Kayla Ngai

Researchers at Osaka University led by Kohji Nishida, an ophthalmologist in Japan, were successfully able to treat corneal disease in four patients in a clinical trial that was provisionally approved in 2019. According to the Illinois Eye Center, Corneal disease is a serious condition that can cause clouding, distortion, scarring, and eventually blindness. Corneal disease is very common among the elderly, but quality tissue for corneal cells is rare to come by. I believe that Japan is making great efforts in medical advancements to help its aging population.

When CBS News covered this topic, they mentioned that the stem cell research was supposed to help cope with the worlds oldest population. However, in the article, they did not go into detail about Japans population. I feel that it is important to talk about Japans elderly because the trials and treatments would be mostly beneficial to them. For starters, a huge majority of Japans population is the elderly (being about 65 years or older). This means that their population is dwindling and many members of their society are suffering from degenerative diseases.

Due to the problems that arise with aging, taking care of the elderly has been difficult. The proportion of older people to the younger generation shows an imbalance, so theres a deficit of people that can care for the elders. Thus, many youths are also not able to work full time.

According to Japan Today, a study from a 2019 labor ministry report showed that about 40% of citizens were only working part-time or as temporary hires. On top of everything, after the pandemic hit, more people lost their jobs. The countrys economy grew unstable. As the middle class isnt making as much money, they are slowly [sink] into poverty. However, the use of stem cells for degenerative diseases may make it easier to take care of elders, as well as help the older generation gain more independence.

The researchers in the corneal disease study used stem cells grown in a lab which are basic building blocks that can be developed into other cells. Specifically, the stem cells that are utilized are induced pluripotent stem (iPS) cells that have been reverted back to the stem state so that they can serve as the building unit for most organ tissue. For the latest cornea study, three of the patients eyesight improved and have been reported with no side effects a year later. The Japanese government has invested $970 million towards iPS technology for regenerative medicine and the idea behind stem cell research is to raise artificial cells to replace the damaged or unhealthy ones in the body.

The iPS solution for corneal implants would be a stepping stone for other medical technologies. There are already discussions surrounding stem cells being used to help treat other disorders. For example, Toru Kimura, Representative Director and Executive Vice President of Sumitomo Dainippon Pharma, is currently working with Kyoto University on a solution to the neurodegenerative disease Parkinsons.

Although Japans population problem is a major concern, the use of iPS stem cells would be an effective way to mediate the issue. The research would make great strides forward not only for Japan but for other countries as well. If more trials go through, the elderly population wouldnt have to suffer as much from various degenerative diseases. They would no longer need as much assistance to look after themselves and the young can take full-time jobs. However, as iPS makes its way to being utilized in society, I think researchers need to find more information about the limitations of iPS and other stem cells.

Even though I think these advancements in medicine are a good thing that would help Japans economy and substantially benefit the elderly population living there, I am also a little skeptical about the long-term effects. For instance, there could be a risk for carcinogens, which are capable of causing cancer. Hence, as with all new medical developments, we need to be wary about the initial success. But for now, the trials attest to great promise!

See original here:
Student Opinion: Stem Cell Treatment Advances Towards A Brighter Future - The Peoples Vanguard of Davis

Cell Isolation/Cell Separation Market Size, Share, Prospects and Upcoming Trends 2021-2030 themobility.club – themobility.club

Global Cell Isolation/Cell Separation MarketSize study, By Product (Consumables, Instruments), By Cell Type (Human Cells {Differentiated Cells, Stem Cells}, Animal Cells), By Cell Source (Bone Marrow, Adipose Tissue, Cord Blood/ Embryonic Stem Cells), By Technique (Centrifugation- Based Cell Isolation, Surface Marker- Based Cell Isolation, Filteration- Based Cell Isolation), By Application (Biomolecule Isolation, Cancer Research, Stem Cell Research, Tissue Regeneration & Regenerative Medicine, In Vitro Diagnostics), By End User (Biotechnology And Biopharmaceutical Companies, Hospitals And Diagnostic Laboratories, Research Laboratories And Institutes, Other End Users), and Regional Forecasts 2022-2028

Global Cell Isolation/Cell Separation Market is valued approximately USD 6.9 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 16.8% over the forecast period 2022-2028.

Request To Download Sample of This Strategic Report: https://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

Cell isolation is also known as cell separation which is a process of isolating one or more specific cell populations from the varied cell combinations. This process can be performed in a variety of intricate biological samples, such as whole peripheral blood and leukapheresis products. Cell separation is a significant component in many life sciences, from stem cell and oncology research to routine clinical diagnosis, thereby, these factors are augmenting the market growth. In addition, the increasing number of government funding for cell-based research, the rising prevalence of cancer and infectious diseases among the population, coupled with growing focus on personalized medicine are the major factors that are stimulating the market demand around the world.

For instance, according to the International Agency for Research on Cancer (IARC), in 2018, there were nearly 17.0 million new cancer cases were recorded and 9.5 million cancer deaths globally 2018. Additionally, the amount is anticipated to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. . However, ethical issues associated with embryonic stem cell isolation and the high cost of cell-based research impede the growth of the market over the forecast period of 2022-2028. Also, technological developments and innovation in cell isolation are anticipated to act as a catalyzing factor for the market demand during the forecast period.

The key regions considered for the globalCell Isolation/Cell Separation Marketstudy include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the availability of the well-established infrastructure for life science research and the presence of the leading market players. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the increasing number of technological developments, as well as the rising prevalence of cancer, would create lucrative growth prospects for the Cell Isolation/Cell Separation Market across the Asia-Pacific region.

DOWNLOAD FREE SAMPLE REPORThttps://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

Major market players included in this report are: Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Limited Beckman Coulter Inc. Terumo BCT GE Healthcare Bio- Rad Laboratories Inc. Corning Inc. Miltenyl Biotech pluriSelect Life Science Akadeum Life Sciences, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:Consumables Instruments

By Cell Type:Human Cells Differentiated Cells Stem Cells Animal Cells

By Cell Source:Bone Marrow Adipose Tissue Cord Blood/ Embryonic Stem Cells

By Technique:Centrifugation- Based Cell Isolation Surface Marker- Based Cell Isolation Filtration- Based Cell Isolation

By Application:Biomolecule Isolation Cancer Research Stem Cell Research Tissue Regeneration & Regenerative Medicine In Vitro Diagnostics

By End User:Biotechnology And Biopharmaceutical Companies Hospitals And Diagnostic Laboratories Research Laboratories And Institutes Other End Users

Directly Purchase the Complete GlobalCell Isolation/Cell SeparationMarket Research Report @https://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

By Region:North America U.S. Canada Europe UK Germany France Spain Italy ROE

Asia Pacific China India Japan Australia South Korea RoAPAC Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2018, 2019, 2020 Base year 2021 Forecast period 2022 to 2028

Target Audience of the Global Cell Isolation/Cell Separation Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investors

Companies Mentioned

Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Limited Beckman Coulter Inc. Terumo BCT GE Healthcare Bio- Rad Laboratories Inc. Corning Inc. Miltenyl Biotech pluriSelect Life Science Akadeum Life Sciences, Inc.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.quadintel.com/request-sample/cell-isolationcell-separation-market/QI037

Table of Contents:

What aspects regarding the regional analysis Market are included in this report?

About Quadintel:

We are the best market research reports provider in the industry. Quadintel believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Quadintel is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Quadintel:Email:sales@quadintel.com Address: Office 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.quadintel.com/

See more here:
Cell Isolation/Cell Separation Market Size, Share, Prospects and Upcoming Trends 2021-2030 themobility.club - themobility.club

Sen. Orrin Hatch’s legacy tracks the GOP’s evolution on health – NPR

Democratic Sen. Ted Kennedy ( left) and Republican Sen. Orrin Hatch teamed up on a series of landmark legislative health care achievements, such as the Ryan White program on AIDS treatment, the Americans with Disabilities Act, and the first major federal child care law. John Duricka/AP hide caption

Democratic Sen. Ted Kennedy ( left) and Republican Sen. Orrin Hatch teamed up on a series of landmark legislative health care achievements, such as the Ryan White program on AIDS treatment, the Americans with Disabilities Act, and the first major federal child care law.

When it comes to health policy, former Utah Republican Sen. Orrin Hatch, who died Saturday at age 88, leaves a complex legacy of major legislative achievements, changing positions, compromises and fierce opposition. In many ways, though, Hatch's evolution and leadership on health policy during his four decades in the U.S. Senate mirror that of the Republican Party.

When he came to Washington as a neophyte politician after an upset victory in 1976, Hatch was a conservative firebrand, one of the early leaders of the "New Right" bent on dismantling the federal welfare state and banning abortion. A former trial lawyer, the new senator had never before held public office.

But the election of Ronald Reagan in 1980 and the Republican takeover of the Senate that made Hatch chairman of the powerful Labor and Human Resources Committee (now the Health, Education, Labor and Pensions Committee) turned him into something of a pragmatist. That pragmatism, it should be noted, was somewhat forced: Even though Hatch was technically the chair, there were enough moderate Republicans on the panel to give the ranking Democrat, Massachusetts' Edward Kennedy, effective control over what could be passed by the committee.

So Hatch learned to compromise and to legislate. In 1984, he negotiated with liberal Rep. Henry Waxman, D-Calif., what is still referred to as the "Hatch-Waxman Act." It's better known as the law that allowed, for the first time, approval of generic copies of brand-name drugs. Although far from a panacea, it is still the single-biggest advance in the fight to rein in high drug prices.

When the Democrats took back the Senate after the 1986 elections, Kennedy became chairman of the committee and Hatch, the ranking Republican. The two teamed up on a series of landmark legislative achievements, from the Ryan White program on AIDS treatment and the Americans with Disabilities Act to the first major federal child care law. And while Hatch was a strong foe of national health insurance, he and Kennedy ultimately pushed through Congress in 1997 the bill to create the Children's Health Insurance Program, which provides low-cost health insurance for low-income families who don't qualify for Medicaid.

The stridently anti-abortion Hatch was outspoken about his support for federal funding for research on embryonic stem cells derived from aborted fetuses. "I think it's the ultimate pro-life position, because I believe being pro-life is not just caring for the unborn but caring for those who are living," he told NPR in 2007.

But like much of the Republican Party in Congress, Hatch returned to his conservative roots after the election of President Barack Obama in 2008. A supporter of the so-called individual mandate requiring people to have health insurance when it was the quasi-official GOP position in the early 1990s, Hatch became an outspoken foe. "Congress has never crossed the line between regulating what people choose to do and ordering them to do it," he said in 2010.

After moderate Utah Republican Sen. Robert Bennett was ousted in a primary in 2010 and replaced by conservative favorite Mike Lee, Hatch grew more conservative to win reelection in 2012. His final term in the Senate was marked by efforts to overturn the Affordable Care Act and further restrict abortion access. The devout Mormon, who in his spare time wrote lyrics for best-selling Christian music, even called the ACA "the stupidest, dumb-a** bill that I've ever seen. Now some of you may have loved it; if you do, you are one of the stupidest dumb-a** people I've ever met." He later apologized for the statement.

A former Kennedy aide, Jim Manley, told The Salt Lake Tribune that "no one epitomizes the rightward lurch of the Republican Party more than Sen. Hatch."

In one final twist, however, Hatch pushed as his successor the 2012 GOP presidential nominee, Mitt Romney. In just his first few years, Romney has become one of the most moderate Republicans in the chamber. That may prove to be Orrin Hatch's final legacy.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. It is an editorially independent operating program of KFF (Kaiser Family Foundation).

Go here to read the rest:
Sen. Orrin Hatch's legacy tracks the GOP's evolution on health - NPR

Global Regenerative Medicine Market To Be Driven By Increasing Clinical Trials During The Forecast Period Of 2021-2026 themobility.club -…

The new report by Expert Market Research titled, GlobalRegenerative Medicine MarketReport and Forecast 2021-2026, gives an in-depth analysis of the global regenerative medicine market, assessing the market based on its segments like technology, applications, and major regions . The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/regenerative-medicine-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

The emergence ofstem celltechnology, the untapped potential of nanotechnology, the rise in prevalence ofchronicdiseases and trauma emergencies, advancements in monitoring devices andsurgicaltechnologies, the rise in incidence of degenerative diseases, and the scarcity of organs for transplantation are all factors driving the growth of this market. Over the forecast period, the market is expected to be driven by rise in modern technology. The market expansion is predicted to be supplemented by a greater focus on stem cells and an increase in R&D activity in emerging markets. The emerging countries are concentrating on technical improvements, which is predicted to promote worldwide market growth. However, the markets expansion is expected to be hampered by government regulations, operational inefficiency, and the high cost of regenerative medicine treatment.

Industry Definition and Major Segments

Regenerative medicine is a branch of tissue engineering and molecular biology concerned with the replacement and regeneration of human cells, tissues, and organs in order to restore normal function. Bone graft alternatives, osteoarticular diseases, dermatological, cardiovascular, central nervous system, and other conditions are all treated with regenerative medicine.

Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/regenerative-medicine-market

By technology, the market is divided into:

Based on applications, the industry can be divided into:

By region, the industry is categorised into:

Latest News on Global Regenerative Medicine Market@https://www.expertmarketresearch.com/pressrelease/regenerative-medicine-market

Market Trends

The high number of clinical trials, growing economic impact on regenerative medicine, emerging applications of gene therapy in regenerative medicine, increasing government and private sector funding to support the development of regenerative medicine, and technological advances in stem cell, tissue engineering, and nanotechnology are driving the global regenerative medicine market. The regenerative medicine market is also being fueled by an increase in strategic partnerships, which aid in the commercialisation of regenerative medicine. Another factor driving up demand for regenerative treatments is the rising prevalence of chronic diseases and hereditary disorders, along with degenerative diseases and bone and joint problems. The high cost of therapy and the regulatory difficulties relating to stem cells, tissues engineering, and regenerative medicine, could stymie the industrys expansion.

The global market was dominated by North America. This is due to the presence of a large number of key players in the United States. The high number of clinical trials in this region is due to the availability of advanced technology and the existence of research institutes working in the development of innovative treatments. Due to the increase of infrastructure and facilities to expedite stem cell research in the regions growing economies, Asia Pacific is expected to have the highest CAGR during the projected period. The Chinese government has approved many research projects involving human embryonic stem cells, encouraging scientists to investigate the cells clinical potential. These factors are expected to boost the market during the foreast period as well.

Key Market Players

The major players in the market are Novartis AG, Vericel, Integra Lifesciences, Mimedx Group, Stryker, Wright Medical, Spark Therapeutics, Osiris Therapeutics, Kite Pharma (Subsidiary of Gilead Sciences), and Organogenesis, among others. The report covers the market shares, capacities, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: EMR Inc. Contact Person: Steven Luke, Corporate Sales Specialist U.S.A. Email:sales@expertmarketresearch.com Toll Free Number: +1-415-325-5166 | +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA City: Sheridan State: Wyoming Country: United States Website:https://www.expertmarketresearch.com

Also, CheckProcurement Intelligencewhich provides you with Infallible research solutions.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Read more:
Global Regenerative Medicine Market To Be Driven By Increasing Clinical Trials During The Forecast Period Of 2021-2026 themobility.club -...

GeneTether Therapeutics Inc. Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights – TheNewswire.ca

Vancouver, British Columbia TheNewswire - April 28, 2022 GeneTether Therapeutics Inc., (together with its wholly-owned subsidiary GeneTether, Inc., GeneTether or the Company) (CSE:GTTX), an early-stage genetic medicine company focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome, announced today the filing of its audited financial statements for the fiscal year ending December 31, 2021 and reported on corporate highlights from 2021. All dollar amounts are presented in the United States dollar, unless otherwise noted. Complete financial statements along with related management and discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada, at http://www.SEDAR.com.

Commenting on the Companys progress, CEO Roland Boivin said, Were pleased with our ability to close our IPO in these difficult market conditions, and we now have the means to significantly advance our R&D plan. In addition to the work currently being done as part of our UC Davis and ZeClinics collaborations,we have initiated the development of strategic plans to generate in vitro and in vivo model systems for uromodulin kidney disease ( [ANNOTATION:

BY 'Keith C. Inman' ON '2022-04-21T12:52:00'KCI NOTE: 'Consider using "uromodulin" and "kidney disease" instead of abbreviated terms']UMOD) with a focus on developing our lead therapeutic in ADTKD. Were also exploring collaboration opportunities with other genetic medicine companies as we believe our GeneTetherTM platform applies to most gene correction/gene complementation strategies, regardless of organ or disease.

R&D and Intellectual Property:

GeneTether achieved significant R&D progress in 2021, as the Company continues to develop best-in-class gene editing therapies based on its proprietary GeneTether platform:

In April 2021, GeneTether initiated an R&D program with ZeClinics of Barcelona, Spain, whereby ZeClinics will conduct a series of experiments in zebrafish embryos to, among other things, demonstrate the editing efficiency and toxicity of gene editing constructs incorporating the GeneTetherTM platform technology versus identical gene editing constructs without the GeneTetherTM platform technology.

In May 2021, GeneTether initiated an R&D program with the University of California, Davis (UCD) whereby researchers at UCD and members of GeneTethers R&D team will conduct a series of experiments in large animal eggs, embryos and embryonic stem cells to, among other things, demonstrate the editing efficiency of the GeneTetherTM platform technology versus identical gene editing constructs without the GeneTetherTM platform technology.

Between October 2021 and March 2022, GeneTether engaged in collaboration discussions with multiple genetic medicines companies based in Cambridge, Massachusetts. Those discussions are ongoing as of the date of this news release.

On February 9, 2022, the Company announced that the United States Patent and Trademark Office issued a Notice of Allowance with respect to a patent entitled Modified Nucleic Acid Editing Systems for Tethering Donor DNA related to its GeneTetherTM platform technology.

Board of Directors, Management, and Advisors

The Company succeeded in attracting high quality management team members and established its Scientific Advisory Board in 2021, creating a best-in-class team within gene therapy:

In January 2021, Mr. Andre Pereira Fraga Figueiredo and Mr. Daren Graham were elected to GeneTethers Board of Directors. Mr. Fraga has over 20 years of experience in MA, strategy, and business development in the petrochemical and renewable energy sectors, and is an active investor in early stage life science companies. Mr. Graham has nearly 20 years of experience in the life science industry as a merchant banker, senior operations executive, and corporate finance attorney. In April 2021, GeneTethers board of directors appointed Mr. Graham as its Chairperson.

In March 2021, the Company engaged Green BCN Consulting Services, a group of Barcelona-based consultants specializing in life science research, drug discovery and development, and strategic planning. Also in March 2021, Dr. Peter Sampson joined the Company as Vice President, Research and Development on a consulting basis. Dr. Sampson has over 20 years of experience in the life science industry, ranging from early-stage research and development to clinical trials.

In October 2021, Mr. Roland Boivin joined GeneTether as its Chief Executive Officer. Mr. Boivin has nearly 25 years of public company leadership experience, with a focus on strategic operations, finance, business development, and general management, including as CFO for Medexus Pharmaceuticals. GeneTethers shareholders also elected Mr. Boivin to the Board of Directors.

In October 2021 Ms. Jean Jen joined GeneTether as its Chief Financial Officer. Ms. Jen has over twelve years of finance and accounting experience, working with both private and public companies in the life sciences industry and in the gene-therapy space, including Nasdaq-listed Arbutus Biopharma Corporation.

In October 2021, GeneTethers Mr. P. Gage Jull jointed the Companys Board of Directors. Mr. Jull is Executive Chairman of Arrow Exploration Corp., a TSX-V listed oil and gas company active in Canada and Colombia. Mr. Jull was also a Co-Founder and Chairman of Bordeaux Capital Inc., a Toronto-based mergers and acquisitions advisory firm focused on emerging companies in the natural resources and other sectors. Mr. Jull is also a director of Tryp Therapeutics Inc. where he is the Chair of the board of directors and Audit Committee.

In October 2021, Dr. Kuldeep Neote joined GeneTether as the Chairperson of its Scientific Advisory Board. GeneTether also engaged Dr. Neote as a consultant for certain of its innovation and strategy activities. Dr. Neote earned his PhD in Molecular Genetics at the University of Toronto. He has over 25 years in the life science industry, including as a researcher at Genentech, Pfizer, and Eli Lilly and Company, and as a business development executive at Johnson Johnson and Eli Lilly and Company. He is currently an Entrepreneur-in-Residence at FACIT/OICR in Toronto and at The National Institutes of Health in Maryland.

Financing and Corporate Restructure

The Company succeeded in completing multiple financings and a corporate reorganization (the Reorganization) to support the ongoing development of its research and development activities:

From February to July 2021, GeneTether conducted a seed round private placement financing for aggregate proceeds of approximately US$1,000,000.

On November 30, 2021, the Company and GT Inc. completed the Reorganization, pursuant to which GeneTether Inc. became a wholly-owned subsidiary of the Company.

On March 29, 2022, the Company announced that it closed its initial public offering and concurrent private placement of units of the Company (the Units) for aggregate gross proceeds of C$4,500,000 at a price of C$0.60 per Unit. Each Unit was comprised of one common share in the capital of the Company (a Common Share), and one Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to acquire one additional Common Share at an exercise price of C$0.72/share until March 29, 2025.

Financial Results

The Companys total assets as at December 31, 2021 were approximately $370,500, including approximately $180,000 in cash. Net and comprehensive loss for the twelve months ended December 31, 2021 were approximately $1,638,000.

About GeneTether

Founded by EGB Ventures founder and managing partner, William J. Garner, M.D., and veteran gene editing researcher, R. Geoffrey Sargent, Ph.D., GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. The Companys wholly-owned platform technology uses a proprietary method to tether donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. The Company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases. GeneTethers proof of concept study demonstrated an approximately 7x higher gene editing efficiency as compared to the same gene editing payload without application of GeneTethers technology.

For more information, visitwww.genetether.com.

Contacts:

Roland Boivin, CEO

(833) 294-4363 ext. 1

roland@genetether.com

Jean Jen, CFO and Corporate Secretary

(833) 294-4363 ext. 2

jean@genetether.com

Forward-Looking Disclaimer

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause GeneTethers actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward-looking statements in this document include the expectation that the Company will significantly advance its research and development plan, expectations that the Company will develop collaboration opportunities with other genetic medicines companies, the expectation that the GeneTetherTM platform technology applies to most other gene correction/gene complementation strategies regardless of organ or disease, and all other statements that are not statements of historical fact.

Although GeneTether believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic; general economic conditions; adverse industry events; future legislative and regulatory developments; the Companys ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of GeneTether to implement its business strategies; competition; the ability of GeneTether to obtain and retain all applicable regulatory approvals and other assumptions, risks and uncertainties, including those set forth under the heading Risk Factors in the Companys final prospectus dated March 21, 2022.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

The Canadian Securities Exchange nor its Regulation Service has approved nor disapproved the contents of this news release

NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

The rest is here:
GeneTether Therapeutics Inc. Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights - TheNewswire.ca

Global Cell Counting Market to be Driven by the Increasing Demand in Hospitals and Diagnostic Laboratories in the Forecast Period of 2021-2026 …

The new report by Expert Market Research titled,GlobalCell Counting MarketReport and Forecast2021-2026, gives an in-depth analysis of theglobal cell counting market, assessing the market based on its segmentslikeproduct type, end use,andmajor regions. Thereport tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along withanalysingthe market based on the SWOT and Porters Five Forces models.

Note 1: For a snapshot of the primary and secondary data of the market (2016-2026), along with business strategies and detailed market segmentation, please click on request sample report. The sample report shall be delivered to you within 24 hours.

Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/cell-counting-market/requestsample

The keyhighlights of the report include:

Market Overview (2016-2026)

During the projection period, hospitals and diagnostic laboratories are estimated to observe significant growth. This can be attributed to an increase in capital expenditure for the development of cell culture-based vaccines and the rapid expansion of the pharmaceutical industry. The rising prevalence of various chronic ailments, such as cancer, HIV-AIDS, leukaemia, Alzheimers, etc., is propelling the demand for cell counting techniques. The growing adoption of cell counting instruments across diverse medical fields, such as molecular biology, immunology, pathology, etc., for developing next-generation therapeutics is also augmenting the market growth. In addition to this, the increasing utilisation of cell counting for the identification and determination of primary tumours, circulating tumours, and metastatic tumour is further bolstering the market growth. The widespread adoption of stem cell therapy is also propelling the demand for various cell counting instruments on a global level.

Industry Definition and Major Segments

Cell counting refers to a technique used to analyse the cells or micelles that are usually suspended in blood or other body fluids. Some of the standard instruments used for cell counting includes hemocytometers, spectrophotometers, flow cytometers, and automated cell counters, among others. Cell counting aids in classifying cell types and detecting disease through probes to develop the best treatment plan for the patient. It also helps in understanding the structure and composition of the cells for chromosome analysis, protein expression, cancer diagnosis, and haematological malignancies, among others.

Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/cell-counting-market

By product type, the industry is segmented into:

The market can be broadly categorised on the basis of end use into:

On the basis ofregion, the industry is divided into:

Market Trends

The rising awareness of numerous benefits of cell counting techniques in immunophenotyping, cell sorting, cell proliferation assays, and intracellular calcium flux is further driving the market growth. The increasing investments by several government bodies in extensive research and development activities pertaining to the fields of biotechnology, oncology stem cell therapeutics, etc., are also bolstering the adoption of cell counting techniques. The presence of an array of medical research and biopharmaceutical businesses is anticipated to drive market growth in the coming years. With the rapid technological advancements, the market is predicted to be driven by innovations in existing products as well as the launch of new data visualisation and analysis tools. The market growth can also be associated with the increase in the number of proteomics and genomics researchers.

Key Market Players

The major players in the marketareThermo Fisher Scientific Inc.,Becton, Dickinson and Company,Bio-Rad Laboratories, Inc.,Beckman Coulter, Inc.,and PerkinElmer Inc.,among others.The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

Read More Reports:-

Global Medical Alert Systems Market:https://www.expertmarketresearch.com/reports/medical-alert-systems-market

Global Extracorporeal Membrane Oxygenation Market:https://www.expertmarketresearch.com/reports/extracorporeal-membrane-oxygenation-market

Global Pet Supplement Market:https://www.expertmarketresearch.com/reports/pet-supplement-market

Global Dental Equipment Market:https://www.expertmarketresearch.com/reports/dental-equipment-market

Global Newborn Screening Market:https://www.expertmarketresearch.com/reports/newborn-screening-market

Global Immunomodulators Market:https://www.expertmarketresearch.com/reports/immunomodulators-market

Global Human Embryonic Stem Cell Market:https://www.expertmarketresearch.com/reports/human-embryonic-stem-cell-market

Global Telmisartan Market:https://www.expertmarketresearch.com/reports/telmisartan-market

Global Smart Medical Devices Market:https://www.expertmarketresearch.com/reports/smart-medical-devices-market

Global Doxorubicin Market:https://www.expertmarketresearch.com/reports/doxorubicin-market

Note 2:As thenovel coronavirus (COVID-19)continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

We also provide state-of-the-art procurement intelligence through our platform,https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market intelligence, supply chain intelligence, procurement analytics, and category insights through our thoroughly researched and infallible market reports, production cost reports, price analysis, and benchmarking.

Informes de Expertos (https://www.informesdeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consultancy services to a broad clientele base across Spanish speaking countries. With our primary focus on the Latin America and Spain markets, our research experts provide relevant and actionable insights into the markets and track major trends, economic developments, and global trade data.

Determined to bring client satisfaction, we make sure that our tailored approach meets the clients unique market intelligence requirements. Our syndicated and customized research reports cover a wide spectrum of industries ranging from pharmaceuticals and food and beverage to packaging, logistics, and transportation.

Media Contact

Company Name: EMR Inc. Contact Person:-Ian Bell, Business Consultant Email:sales@expertmarketresearch.com Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA City: Sheridan State: Wyoming Country: United States Website:https://www.expertmarketresearch.com

Read more:https://expertmarketresearch-emr.blogspot.com/

**We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Explore more onProcurement Intelligenceservices of EMR Inc.

Read the rest here:
Global Cell Counting Market to be Driven by the Increasing Demand in Hospitals and Diagnostic Laboratories in the Forecast Period of 2021-2026 ...

Embryonic Stem Cell Research | Voices in Bioethics

Introduction

In November 1998, two teams of U.S. scientists confirmed successful isolation and growth of stems cells obtained from human fetuses and embryos. Since then, research that utilizes human embryonic cells has been a widely debated, controversial ethical issue. Human embryonic cells possess the ability to become stem cells, which are used in medical research due to two significant features. First, they are unspecialized cells, meaning they can undergo cell division and renew themselves even with long periods of inactivity. Secondly, stem cells are pluripotent, with the propensity to be induced to become specified tissue or any organ-specific cells with special functions depending on exposure to experimental or physiologic conditions, as well as undergo cell division and become cell tissue for different organs.

The origin of stem cells themselves encapsulates the controversy: embryonic stem cells, originate from the inner cell mass of a blastocyst, a 5-day pre-implantation embryo. The principal argument for embryonic stem cell research is the potential benefit of using human embryonic cells to examine or treat diseases as opposed to somatic (adult) stem cells. Thus, advocates believe embryonic stem cell research may aid in developing new, more efficient treatments for severe diseases and ease the pain and suffering of numerous people. However, those that are against embryonic stem cell research believe that the possibility of scientific benefits of research do not outweigh the immoral action of tampering with the natural progression of a fetal development and interfering with the human embryos right to live. In light of these two opposing views, should embryonic stem cells be used in research? It is not ethically permissible to destroy human embryonic life for medical progress.

Personhood and the Scientific Questionability of Embryonic Stem Cell Research

The ethics behind embryonic stem cell research are controversial because the criteria of personhood is notoriously unclear. Personhood is defined as the status of being a person, entitled to moral rights and legal protections that are higher than living things that are not classified as persons. Thus, this issue touches on existential questions such as: When does life begin? and What is the moral status that an embryo possesses? There is a debate on when exactly life begins in embryonic development and when the individual receives moral status. For example, some may ascribe life starting from the moment of fertilization, others may do so after implantation or the beginning of organ function. However, since the zygote is genetically identical to the embryo, which is also genetically identical to the fetus, and, by extension, identical to the baby, inquiring the beginning of personhood can lead to an occurrence of the Sorites paradox, also acknowledged as the paradox of the heap.

The paradox of the heap arises from vague predicates in philosophy. If there is a heap of sand and a grain is taken away from that heap one by one, at what point will it no longer be considered a heap what classifies it as a heap? The definition of life is similarly arbitrary. When, in the development of a human being, is an embryo considered a person with moral standing? The complexity of the ethics of embryonic stem cell research, like the Sorites paradox, demonstrates there is no single, correct way to approach a problem; thus, there may be multiple different solutions that are acceptable. Whereas the definition of personhood cannot be completely resolved on a scientific basis, it serves a central role in the religious, political, and ethical differences within the field of embryonic stem cell research. Some ethicists attempt to determine what or who is a person by setting boundaries (Baldwin & Capstick, 2007).

Utilizing a functionalist approach, supporters of embryonic stem cell research argue that to qualify as a person, the individual must possess several indicators of personhood, including capacity, self-awareness, a sense of time, curiosity, and neo-cortical function. Proponents argue that a human embryo lacks these criteria, thereby is not considered a person and thus, does not have life and cannot have a moral status. Supporters of stem cell research believe a fertilized egg is just a part of another persons body until the cell mass can survive on its own as a viable human. They further support their argument by noting that stem cell research uses embryonic tissue before its implantation into the uterine wall. Researchers invent the term pre-embryo to distinguish a pre-implantation state in which the developing cell mass does not have the full respects of an embryo in later stages of embryogenesis to further support embryonic stem cell research. Based on this reductionist view of life and personhood, utilitarian advocates argue that the result of the destruction of human embryos to harvest stem cells does not extinguish a life. Further, scientists state that any harm done is outweighed by the potential alleviation of the suffering enduring by tremendous numbers of people with varying diseases. This type of reasoning, known as Benthams Hedonic (moral) calculus, suggests that the potential good of treating or researching new cures for ailments such as Alzheimers disease, Parkinsons disease, certain cancers, etc. outweighs any costs and alleviate the suffering of persons with those aliments. Thus, the end goal of stem cell use justifies sacrificing human embryos to produce stem cells, even though expending life is tantamount to murder. Opponents of embryonic stem cell research would equate the actions done to destroy the embryos as killing. Killing, defined as depriving their victims of life, will therefore reduce their victims to mere means to their own ends. Therefore, this argument touches on the question: if through the actions of embryotic stem cell research is morally indistinguishable from murder? (Outka, 2013). The prohibition of murder extends to human fetuses and embryos considering they are potential human beings. And, because both are innocent, a fetus being aborted and an embryo being disaggregated are direct actions with the intention of killing. Violating the prohibition of murder is considered an intolerable end. We should not justify this evil even if it achieves good. Under the deontological approach, whether a situation is good or bad depends on whether the action that brought it about was right or wrong, hence the ends do not justify the means. Therefore, under this feeble utilitarian approach, stem cell research proceeds at the expense of human life than at the expense of personhood.

One can reject the asserted utilitarian approach to stem cell research as a reductionist view of life because the argument fails to raise ethical concerns regarding the destruction embryonic life for the possibility of developing treatments to end certain diseases. The utilitarian approach chooses potential benefits of stem cell research over the physical lives of embryos without regard to the rights an embryo possesses. Advocates of embryonic stem cell research claim this will cure diseases but there is a gap in literature that confirms how many diseases these cells can actually cure or treat, what diseases, and how many people will actually benefit. Thus, killing human embryos for the potentiality of benefiting sick people is not ethically not ethically permissible.

Where the argument of personhood is concerned, the development from a fertilized egg (embryo) to a baby is a continuous process. Any effort to determine when personhood begins is arbitrary. If a newborn baby is a human, then surely a fetus just before birth is a human; and, if we extend a few moments before that point, we would still have a human, and so on all the way back to the embryo and finally to the zygote. Although an embryo does not possess the physiognomies of a person, it will nonetheless become a person and must be granted the respect and dignity of a person. Thus, embryotic stem cell research violates the Principle of Full Human Potential, which states: Every human being [] deserves to be valued according to the full level of human development, not according to the level of development currently achieved. As technology advances, viability outside the womb inches ever closer to the point of inception, making the efforts to identify where life begins after fertilization ineffectual. To complicate matters, as each technological innovation arrives, stem-cell scientists will have to re-define the start of life as many times as there are new technological developments, an exhausting and never-ending process that would ultimately lead us back to moment of fertilization. Because an embryo possesses all the necessary genetic information to develop into a human being, we must categorically state that life begins at the moment of conception. There is a gap in literature that deters the formation of a clear, non-arbitrary indication of personhood between conception and adulthood. Considering the lack of a general consensus of when personhood begins, an embryo should be referred to as a person and as morally equivalent to a fully developed human being.

Having concluded that a human embryo has the moral equivalent of a fully-fledged human being, this field of research clearly violates the amiable rights of personhood, and in doing so discriminates against pre-born persons. Dr. Eckman asserts that every human being has a right to be protected from discrimination. Thus, every human, and by extension every embryo, has the right to life and should not be discriminated against their for developmental immaturity. Therefore, the field of embryonic stem cell research infringes upon the rights and moral status of human embryos.

Principle of Beneficence in Embryonic Stem Cell Research

The destruction of human embryos for research is not ethically permissible because the practice violates the principle of beneficence depicted in the Belmont Report, which outlines the basic ethical principles and guidelines owed to human subjects involved in research. Stem cell researchers demonstrate a lack of respect for the autonomy and welfare of the human embryos sacrificed in stem cell research.

While supporters of embryonic stem cell research under the utilitarian approach argue the potential benefits of the research, the utilitarian argument however violates the autonomy of the embryo and its human rights, as well as the autonomy of the embryo donors and those that are Pro-Life. Though utilitarian supporters argue on the basis of rights, they exclusively refer to the rights of sick individuals. However, they categorically ignore the rights of embryos that they destroy to obtain potential disease curing stem cells. Since an embryo is regarded as a human being with morally obligated rights, the Principle of Beneficence is violated, and the autonomy and welfare of the embryo is not respected due to the destruction of an embryo in stem cell research. Killing embryos to obtain stem cells for research fails to treat embryos as ends in an of themselves. Yet, every human ought to be regarded as autonomous with rights that are equal to every other human being. Thus, the welfare of the embryo is sacrificed due to lack of consent from the subject.

The Principle of Beneficence is violated when protecting the reproductive interests of women in infertility treatment, who are dependent on the donations of embryos to end their infertility. Due to embryonic stem cell research, these patients prospects of reproductive success may be compromised because there are fewer embryos accessible for reproductive purposes. The number of embryos necessary to become fully developed and undergo embryonic stem cell research will immensely surpass the number of available frozen embryos in fertility clinic, which also contributes to the lack of embryos available for women struggling with infertility. Therefore, the basis of this research violates womens reproductive autonomy, thus violating the Principle of Beneficence.

It is also significant to consider the autonomy and welfare of the persons involved. The autonomous choice to donate embryos to research necessitates a fully informed, voluntary sanction of the patient(s), which poses difficulty due to the complexity of the human embryonic stem cell research. To use embryos in research, there must be a consensus of agreement from the mother and father whose egg and sperm produced the embryo. Thus, there has to be a clear indication between the partners who has the authority or custody of the embryos, as well as any third party donors of gametes that could have been used to produce the embryo because these parties intentions for those gametes may solely have been for reproductive measures only. Because the researchers holding dispositional authority over the embryos may exchange cell lines and its derivatives (i.e., genetic material and information) with other researchers, they may misalign interests with the persons whose gametes are encompassed within the embryo. This mismatch of intent raises complications in confidentiality and autonomy.

Lastly, more ethical complications arise in the research of embryonic stem cells because of the existence viable alternatives that to not destroy human embryos. Embryonic stem cells themselves pose as a higher health risk than adult stem cells. Embryonic stem cells have a higher risk of causing tumor development in the patients body once the cells are implanted due to their abilities to proliferate and differentiate. Embryonic stem cells also have a high risk of immunorejection, where a patients immune system rejects the stem cells. Since the embryonic stem cells are derived from embryos that underwent in vitro fertilization, when implanted in the body, the stem cells marker molecules will not be recognized by the patients body, resulting in the destruction of the stem cells as a defensive response to protect the body (Cahill, 2002). With knowledge of embryonic stem cells having higher complications than the viable adult stem cells continued use of embryonic stem cells violates the Principle of Beneficence not only for the embryos but for the health and safety of the patients treated with stem cells. Several adult stem cell lines (undifferentiated cells found throughout the body) exist and are widely used cell research. The use of adult stem cells represents research that does not treat human beings as means to themselves, thus, complying with the Principle of Beneficence. This preferable alternative considers the moral obligation to discover treatments, and cures for life threating diseases while avoiding embryo destruction.

Conclusion

It is not ethically permissible to destroy human embryonic life for medical progress due to the violations of personhood and human research tenets outlined in the Belmont Report. It is significant to understand the ethical implications of this research in order to respect the autonomy, welfare, beneficence, and basic humanity afforded to all parties involved. Although embryonic stem cell research can potentially provide new medical advancements to those in need, the harms outweigh the potential, yet ill-defined benefits. There are adult stem cell alternatives with equivalent viability that avoid sacrificing embryos. As society further progresses, humans must be cautious of compromising moral principles that human beings are naturally entitled to for scientific advancements. There are ethical boundaries that are crossed when natural processes of life are altered or manipulated. Though there are potential benefits to stem cell research, these actions are morally and ethically questionable. Thus, it is significant to uphold ethical standards when practicing research to protect the value of human life.

References

Shamblott, M. J., J. Axelman, S. Wang, E. M. Bugg, J. W. Littlefield, P. J. Donovan, P. D. Blumenthal, G. R. Huggins, and J. D. Gearhart. Derivation of Pluripotent Stem Cells from Cultured Human Primordial Germ Cells. Proceedings of the National Academy of Sciences 95, no. 23 (November 10, 1998): 1372631. doi:10.1073/pnas.95.23.13726.

National Institutes of Health, U.S. Department of Health and Human Services. Stem Cell Basics I. Stem Cell Information, 2016. https://stemcells.nih.gov/info/basics/1.htm.

Kitwood, Thomas Marris., Clive Baldwin, and Andrea Capstick. Tom Kitwood on Dementia: A Reader and Critical Commentary. Maidenhead, Berkshire: McGraw-Hill/Open University Press, 2007.

University of Michigan. Stem Cell Research: Frequently Asked Questions, 2013. http://www.stemcellresearch.umich.edu/overview/faq.html#section2.

EuroStemCell. Origins, Ethics and Embryos: The Sources of Human Embryonic Stem Cells, 2016. https://www.eurostemcell.org/origins-ethics-and-embryos-sources-human-embryonic-stem-cells.

Perry, David L. Some Issues in Contemporary Neurological Science and Technology, 2011. https://www.scu.edu/ethics/focus-areas/bioethics/resources/ethics-and-personhood/.

Swirsky, E. Week Fourteen Unit: Minute Paper 5 [Blackboard Assignment], 2018.

OMathna, DP. Personhood in Bioethics and Biomedical Research. Research Practitioner 7 (2006): 16774.

Grobstein, C. External Human Fertilization. Scientific American 240, no. 6 (June 1979): 5767.

Mastin, L. Deontology, 2009. https://www.philosophybasics.com/branch_deontology.html.

Spitzer, Robert. Introduction and Principles of Ethics. In Ten Universal Principles: A Brief Philosophy of the Life Issues, xixii, 1-3, 20-29. San Fransisco, CA: Ignatius Press, 2011. https://www.catholiceducation.org/en/religion-and-philosophy/philosophy/introduction-amp-principles-of-ethics.html.

Eckman, Jim. Human Embryonic Stem Cell Research. Issues In Perspective, 2011. https://graceuniversity.edu/iip/2011/05/14-2/.; Eckman, Jim. The Devaluing of Life in America. Issues In Perspective, 2015. https://graceuniversity.edu/iip/2015/09/the-devaluing-of-life-in-america/.

Outka, Gene (2009) "The Ethics of Embryonic Stem Cell Research and the Principle of "Nothing is Lost","Yale Journal of Health Policy, Law, and Ethics: Vol. 9 : Iss. 3 , Article 7.

Curzer, Howard. The Ethics Of Embryonic Stem Cell Research. The Journal of Medicine and Philosophy 29, no. 5 (October 1, 2004): 53362. doi:10.1080/03605310490514225.

Lo, Bernard, and Lindsay Parham. Ethical Issues in Stem Cell Research. Endocrine Reviews 30, no. 3 (May 2009): 20413. doi:10.1210/er.2008-0031.

Hubbard, James. Embryonic Stem-Cell Research: Experts Debate Pros and Cons. The Survival Doctor, 2013. http://thesurvivaldoctor.com/2013/02/14/doctors-debate-embryonic-stem-cell-research-pros-and-cons/.

Koch, Valerie Gutmann, Beth E. Roxland, Barbara Pohl, and Sarah K. Keech. Contemporary Ethical Issues in Stem Cell Research. In Stem Cells Handbook, 2937. New York, NY: Springer New York, 2013. doi:10.1007/978-1-4614-7696-2_2.

Cahill, Lisa Sowle. "Holland, Suzanne, Karen Lebacqz, and Laurie Zoloth, Eds. The Human Embryonic Stem Cell Debate: Science, Ethics, and Public Policy." The National Catholic Bioethics Quarterly 2, no. 3 (2002): 559-62. doi:10.5840/ncbq20022344.

Devolder, Katrien. The Ethics of Embryonic Stem Cell Research. Oxford University Press, 2015. doi:10.1093/acprof:oso/9780199547999.001.0001.

ScienceDaily. Adult Stem Cell, 2018. https://www.sciencedaily.com/terms/adult_stem_cell.htm.

The rest is here:
Embryonic Stem Cell Research | Voices in Bioethics

Researchers Share Insights about Mechanisms of Human Embryo and Create Method to Develop Transcriptionally Similar Cells in Tissue Culture – Newswise

UNDER EMBARGO UNTIL APRIL 28, 2022 at 11:00 AM E

Paper Title: Identification of a retinoic acid-dependent hemogenic endothelial progenitor from human pluripotent stem cells

Journal: Nature Cell Biology

Authors:Christopher Sturgeon, PhD, Associate Professor of Cell, Developmental & Regenerative Biology and Medicine, Hematology & Medical Oncology in the Black Family Stem Cell Institute at the Icahn School of Medicine at Mount Sinai, and other coauthors.

Bottom Line:Blood-forming stem cells found in bone marrow are the life-saving component used in bone marrow transplants. However, suitable donors often cannot be found in many cases. This study reveals how the human embryo develops the precursor to blood-forming stem cells, which researchers say can be used in the novel method they developed to generate blood-forming stem cells from cells in tissue culture.

The studyled by researchers from Mount Sinai and the San Raffaele Telethon Institute for Gene Therapy in Milan Italyconfirms many aspects of cell development, including origins and regulation, which are known to occur within both the mouse and human embryo. In the mammalian embryo, blood-forming stem cells emerge from a specialized cell type called hemogenic endothelium. These cells develop in response to a critical signal pathway known as retinoic acid, which is essential for growth. Their analysis found that stem cell populations derived from human pluripotent stem cells were transcriptionally similar to cells in the early human embryo.

Results: For years, researchers in the field of regenerative medicine have been able to obtain hemogenic endothelium from embryonic stem cells, but these cells do not produce blood-forming stem cells. In the embryo, blood-forming stem cell development requires signaling by retinoic acid. But, current state-of-the-art methods for deriving blood progenitors from human pluripotent stem cells do so in the absence of retinoic acid. In this latest study, researchers examined the dependence on retinoic acid in early cell types derived from human pluripotent stem cells. They performed single cell RNA sequencing of stem cells in vitro to better understand patterns of mesodermal cell types during early development. The research team identified a new strategy to obtain cells that are transcriptionally similar to those hemogenic endothelial cells found in the human embryo by stimulating a very discrete original population with retinoic acid.

Why the Research Is Interesting:This new method brings researchers and scientists closer to developing blood-forming stem cells in tissue culture, but also provides a pathway to establishing specialized blood cell types for transfusions and other treatments for cancer since the new method makings it possible to obtain the same original cells in adult blood that are found in a developing embryo.

Said Mount Sinai's Dr. Christopher Sturgeon of the research: We have made a major breakthrough in our ability to direct the development of stem cells in a tissue culture dish into cells that have the same gene expression signature as the immediate progenitor of a blood-forming stem cell found in the developing embryo. With this, now we can focus our efforts at understanding how to capture embryonic blood-forming stem cells, with the goal of using them as a substitute for bone marrow.

Researchers from the Washington University School of Medicine in St. Louis, MO contributed to this study.

###

See the rest here:
Researchers Share Insights about Mechanisms of Human Embryo and Create Method to Develop Transcriptionally Similar Cells in Tissue Culture - Newswise

Development and regulation of stem cellbased therapies in China – Newswise

Background

Clinical researches of stem cell-based therapies are highly active in China, while it was arduous to determine the most effective way of clinical translation of those advanced therapies.

This article briefly introduced the regulatory framework development, the progress in stem cell clinical researches and clinical trials of commercially developed stem cell-based products, as well as the clinical review concerns of stem cell-based products in China.

The current regulatory framework of stem cell clinical researches in China was launched in 2015, when regulatory authorities issued Administrative Measures on Stem Cell Clinical Research (AMSCCR) detailing the rules of stem cell clinical research. Thereafter, the rapidly growing stem cell clinical researches were rigorously managed and clinical use of stem cell therapy was halted. Meanwhile, commercially developed stem cell-based products are supervised by Drug Administration Law (DAL).

The regulatory framework of stem cell-based therapy in China has progressed in the last few decades, which is currently regulated according to AMSCCR and DAL. Well-designed and patient-focused clinical trial is required for commercially developed stem cell-based products, and definite clinical benefit evidence is crucial to obtain marketing authorization.

Read more:
Development and regulation of stem cellbased therapies in China - Newswise

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner … – The Bakersfield Californian

Cellectis is developing custom TALEN for Cytovia to develop gene-edited iPSC-derived Natural Killer cellsCytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreementand combined company is expected to be listed on NASDAQ under the ticker symbol INKC$20 million noterepresents upfrontcollaboration consideration and would convert into common stock upon completion of the business combination

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (the Company) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces today that its partner Cytovia Therapeutics, LLC (Cytovia), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, entered into a definitive business combination agreement with Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLE) (Isleworth), a Special Purpose Acquisition Company (SPAC).

Concurrent with the business combination agreement, Cellectis received a $20 million convertible note in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement entered between Cellectis and Cytovia in February 2021. The terms of the note provide for conversion into common stock of the combined company upon completion of the business combination, which is subject to the satisfaction or waiver of customary closing conditions. In connection with this convertible note, Cellectis received a warrant to purchase additional shares of the combined company representing up to 35% of the shares issued upon conversion of the note at a predetermined exercise price, with the number of shares issuable upon exercise and the exercise subject to certain adjustments.

We are impressed by the progress Cytovia has accomplished in the past months. Cytovia shares Cellectis mission to provide life-saving off-the-shelf allogeneic cell therapies to patients, and we are excited to be providing them with best-in-class TALEN gene editing for cell therapy applications. Congratulations to the Cytovia team for this transaction, which is an important milestone as they continue their journey to progress gene-edited NK therapeutics towards a cure for cancer! said Andr Choulika, CEO of Cellectis.

Cellectis and Cytovias research and development collaboration:

In February 2021, Cellectis and Cytovia entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells. In November 2021, Cellectis and Cytovia extended their collaboration to include new CAR target and development in China by Cytovias strategic partner, CytoLynx Therapeutics.

Financial terms of the collaboration include the $20 million convertible note as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia.

Cellectis is developing custom TALEN, which Cytovia uses to edit iPSCs. Cytovia is responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and is conducting the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis has granted Cytovia a worldwide license under the patent rights over which Cellectis has control in this field, including in China, in order for Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit http://www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as anticipate, believe, intend, expect, plan, scheduled, could and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the business combination of Cytovia and Isleworth, the conversion of the convertible note, the progress and advancement of the research collaboration with Cytovia, and the receipt by Cellectis of development, regulatory, and sales milestones and royalty payments from Cytovia. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development, market conditions, and the ability of Cytovia and Isleworth to satisfy the conditions of the business combination agreement. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities and Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

About Cytovia

Cytovia aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. Cytovia is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN gene-edited iNK cells with improved function and persistence, and TALEN gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovias proprietary Flex-NK technology.

These two technology platforms are being used to develop treatment of patients with solid tumors such as HCC and Glioblastoma as well as hematological malignancies such as Refractory Multiple Myeloma.

Headquartered in Aventura, FL, Cytovia has research and development laboratories in Natick, MA, and a GMP cell manufacturing facility in Puerto Rico. The companys own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation and the University of California San Francisco (UCSF).

Cytovia has a strategic partnership with CytoLynx Therapeutics, which is focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

For further information on Cellectis, please contact:

Media contacts: Pascalyne Wilson,Director,Communications,+33 (0)7 76 99 14 33, media@cellectis.com Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact: Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com Ashley R. Robinson, LifeSci Advisors, +1 617430 7577

Attachment

Read more:
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner ... - The Bakersfield Californian